Premium
Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin‐like growth factor binding protein‐2
Author(s) -
CHATTERJEE SHILLA,
PARK EUN SUNG,
SOLOFF MELVYN S.
Publication year - 2004
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2004.00898.x
Subject(s) - du145 , medicine , prostate cancer , insulin like growth factor binding protein , insulin like growth factor , cancer research , growth factor , cancer , insulin , endocrinology , receptor , lncap
Background: Insulin‐like growth factor binding protein‐2 (IGFBP‐2) is expressed by all human prostate cancer cell lines and dramatically increases in the serum of prostate cancer patients. However, the role of IGFBP‐2 in prostatic tumorigenesis is not known. The aim of the present study was to investigate the effects of IGFBP‐2 on the proliferation of DU145 human prostate cancer cells in culture. Methods: Using cell proliferation assays, we examined the effects of exogenously administered and endogenously modulated levels of IGFBP‐2 on the proliferation of DU145 cells. Result: Cell growth was stimulated by exogenously administered IGFBP‐2, but significantly retarded ( P < 0.05) by its neutralizing antibody. Overexpression of IGFBP‐2 by transfection also stimulated cell growth, which was significantly ( P < 0.05) inhibited in transfectants expressing antisense mRNA to IGFBP‐2. Furthermore, the proliferation of IGFBP‐2 overexpressing cells was significantly dampened by exogenously administered IGFBP‐2 antibody. Conclusions: IGFBP‐2 is an autocrine growth factor for DU145 human prostate cancer cells and cell proliferation can be significantly retarded by neutralizing or inhibiting its synthesis. These findings provide a strong rationale for targeting IGFBP‐2 in the testing of novel strategies to treat prostate cancer.